<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11397">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00577655</url>
  </required_header>
  <id_info>
    <org_study_id>IXR-302-25-105</org_study_id>
    <nct_id>NCT00577655</nct_id>
  </id_info>
  <brief_title>Chronic-Dose Safety and Efficacy Study of an Albuterol Metered Dose Inhaler (MDI) Inhaler Using a Hydrofluoroalkane (HFA) Propellant In Pediatric Asthmatics</brief_title>
  <official_title>Phase 3 Study to Evaluate the Chronic-dose Safety and Efficacy of Albuterol-HFA-MDI Relative to Placebo in Pediatric Asthmatics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Branded Pharmaceutical Products, R&amp;D Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Branded Pharmaceutical Products, R&amp;D Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the chronic-dose and efficacy of
      Albuterol-HFA-MDI relative to placebo in pediatric asthmatics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients will be randomized to receive one of the following two treatments four
      times a day for 21 days:

      Placebo in a metered-dose inhaler using a hydrofluoroalkane propellant (Placebo-HFA-MDI).

      180 mcg of Albuterol in a metered-dose inhaler using a hydrofluoroalkane propellant
      (Albuterol-HFA-MDI)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Maximum Percent Change From Baseline</measure>
    <time_frame>2 hours following completion of dosing on Day 22</time_frame>
    <safety_issue>No</safety_issue>
    <description>The FEV1 test is conducted by having a person blow as hard as they can into a mouthpiece attached to a sensor that measures the amount of air blown over time. The maximum percent change from baseline in the Forced Expiratory Volume in one second (FEV1) observed up to 2 hours following completion of dosing using Day 22 baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Percent Change in Peak Expiratory Flow (PEF)</measure>
    <time_frame>Day 22</time_frame>
    <safety_issue>No</safety_issue>
    <description>The PEF test is conducted by having a person blow as hard as they can into a mouthpiece attached to a sensor that measures the amount of air blown over time. Maximum percent change in Peak Expiratory Flow (PEF) observed up to 2 hours following completion of dosing using Day 22 baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline Adjusted Area-under-the-effect-curve for Percent of Predicted FEV1 Over 6 Hours Post Dose</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline-adjusted area-under-the Effect Curve for Percent of Predicted FEV1 Over 6 Hours Post-dose on Day 22.</measure>
    <time_frame>Day 22</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline-adjusted area-under-the Effect Curve for PEF Over 6 Hours Post-dose.</measure>
    <time_frame>Day 22</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Time (in Minutes) to Response Onset: the First Time That an Increase From Baseline in FEVl of at Least 15% is Noted in Participants Who Responded to the Medication.</measure>
    <time_frame>Day 22</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Time (in Minutes) to Response Onset: the First Time That an Increase From Baseline in PEF of at Least 15% is Noted</measure>
    <time_frame>Day 22</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Time (in Minutes) to Response Onset: the First Time That an Increase From Baseline in FEVl of at Least 12% is Noted</measure>
    <time_frame>Day 22</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Time (in Minutes) to Response Onset: the First Time That an Increase From Baseline in PEF of at Least 12% is Noted</measure>
    <time_frame>Day 22</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Time (in Minutes) to Maximum FEVl</measure>
    <time_frame>Day 22</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Time (in Minutes) to Maximum PEF</measure>
    <time_frame>Day 22</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Duration of Effect (in Hours) as Measured From the Time of Dosing to the Time at Which the FEVl First Decreases Below 15%</measure>
    <time_frame>Day 22</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Duration of Effect (in Hours) as Measured From the Time of Dosing the Time at Which the FEVl First Decreases Below 12%</measure>
    <time_frame>Day 22</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Duration of Effect (in Hours) as Measured From the Time of Dosing the Time at Which the PEF First Decreases Below 15%</measure>
    <time_frame>Day 22</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Duration of Effect (in Hours) as Measured From the Time of Dosing the Time at Which the PEF First Decreases Below 12%</measure>
    <time_frame>Day 22</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Highest Daily Asthma Symptom Scores by Study Week</measure>
    <time_frame>Week 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Highest daily asthma symptom scores by study week. For this assessment, patients self-evaluate and record on the diary card the following asthma symptoms experienced during the day (i.e. last 12-14 hours): wheeze, shortness of breath, cough, tightness of chest. The worst of these symptoms will be scored daily as 0 = No symptoms occurred, 1 = Symptom occurred but did not interfere with daily activity, 2 = Symptom occurred but was sometimes annoying or interfered with daily activity, 3 = Symptom present even at rest and was annoying or interfered with daily activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Asthma-related Nocturnal Awakenings Per Week Requiring the Use of Rescue Medication</measure>
    <time_frame>Week 3</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Daily a.m. Pre-dose PEF</measure>
    <time_frame>Week 3</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Average Number of Puffs of Rescue Medication Per 24 Hour Period</measure>
    <time_frame>Week 3</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>180 mcg of Albuterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing with 180 mcg of albuterol in a metered-dose inhaler (MDI) utilizing a hydrofluoroalkane (HFA) propellant. (Hereafter noted as &quot;Albuterol HFA-MDI.&quot;)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A placebo of a metered-dose inhaler (MDI) utilizing a hydrofluoroalkane (HFA) propellant. (Hereafter noted as &quot;Placebo-HFA-MDI.&quot;)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albuterol</intervention_name>
    <description>Albuterol HFA MDI 180 mcg</description>
    <arm_group_label>180 mcg of Albuterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo HFA MDI</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female child aged 4-11 years, inclusive Asthma of a minimum of six months
             duration that has been stable for at least four weeks prior to screening.

        Exclusion Criteria:

          -  Hospitalization for acute asthma exacerbation greater than two years in 12 months
             prior to screening and/or received ER treatment or hospitalization for asthma
             exacerbation.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teva Study Physician MD</last_name>
    <role>Study Director</role>
    <affiliation>TEVA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pediatric Care Medical Group, Inc.</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Allergy &amp; Asthma Medical Group</name>
      <address>
        <city>Palmdale</city>
        <state>California</state>
        <zip>93551</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Trials, LLC</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Research Group, Inc</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Trials of Sacramento</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95823</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carlos Piniella, MD</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sneeze, Wheeze &amp; Itch Associates, Inc.</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma &amp; Allergy Associates, PC</name>
      <address>
        <city>Elmira</city>
        <state>New York</state>
        <zip>14901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENT &amp; Allergy Associates</name>
      <address>
        <city>Newburgh</city>
        <state>New York</state>
        <zip>12550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth's Children Health Center</name>
      <address>
        <city>Utica</city>
        <state>New York</state>
        <zip>13502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Allergy &amp; Asthma Consultants</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute of Southern Oregan, PC</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Adult &amp; Pediatric Allergy &amp; Asthma</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <lastchanged_date>April 11, 2012</lastchanged_date>
  <firstreceived_date>December 18, 2007</firstreceived_date>
  <firstreceived_results_date>July 21, 2009</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric, asthma, albuterol-HFA and Placebo</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Albuterol</title>
          <description>Albuterol-HFA-MDI 180 mcg, four times a day</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo-HFA-MDI</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52">This number represents the number of participants randomized.</participants>
                <participants group_id="P2" count="51">This number represents the number of participants randomized.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Patient Request</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Albuterol</title>
          <description>Albuterol-HFA-MDI 180 mcg, four times a day</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo-HFA-MDI</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="52"/>
                <measurement group_id="B2" value="51"/>
                <measurement group_id="B3" value="103"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <sub_title>Age</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8.3" spread="1.82"/>
                <measurement group_id="B2" value="8.2" spread="2.09"/>
                <measurement group_id="B3" value="8.2" spread="1.95"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="39"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="33"/>
                <measurement group_id="B2" value="31"/>
                <measurement group_id="B3" value="64"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="52"/>
                <measurement group_id="B2" value="51"/>
                <measurement group_id="B3" value="103"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Percent Change From Baseline</title>
        <description>The FEV1 test is conducted by having a person blow as hard as they can into a mouthpiece attached to a sensor that measures the amount of air blown over time. The maximum percent change from baseline in the Forced Expiratory Volume in one second (FEV1) observed up to 2 hours following completion of dosing using Day 22 baseline.</description>
        <time_frame>2 hours following completion of dosing on Day 22</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-To-Treat (ITT) population, day 22 with Last Observation Carried Forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Albuterol</title>
            <description>Albuterol-HFA-MDI 180 mcg, four times a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-HFA-MDI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Maximum Percent Change From Baseline</title>
            <description>The FEV1 test is conducted by having a person blow as hard as they can into a mouthpiece attached to a sensor that measures the amount of air blown over time. The maximum percent change from baseline in the Forced Expiratory Volume in one second (FEV1) observed up to 2 hours following completion of dosing using Day 22 baseline.</description>
            <units>Percentage of change</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12.849" spread="1.005"/>
                  <measurement group_id="O2" value="9.353" spread="1.017"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The formula used to calculate the percentage of maximum change over two hours from dosing is [[(Maximum FEV1 minus Baseline FEV1)divided by Baseline FEV1] times 100]</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0138</p_value>
            <method>ANCOVA</method>
            <method_desc>P value from ANCOVA with the terms for treatment, center, baseline as covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Adjusted Area-under-the-effect-curve for Percent of Predicted FEV1 Over 6 Hours Post Dose</title>
        <description>Baseline</description>
        <time_frame>Day 1</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT, Day 1 baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Albuterol</title>
            <description>Albuterol-HFA-MDI 180 mcg, four times a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-HFA-MDI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Baseline Adjusted Area-under-the-effect-curve for Percent of Predicted FEV1 Over 6 Hours Post Dose</title>
            <description>Baseline</description>
            <units>Percent of Predicted FEV1 * Hours</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25.060" spread="6.748"/>
                  <measurement group_id="O2" value="24.167" spread="6.773"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.9240</p_value>
            <method>ANOVA</method>
            <method_desc>P-value from ANOVA with terms for treatment and center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline-adjusted area-under-the Effect Curve for Percent of Predicted FEV1 Over 6 Hours Post-dose on Day 22.</title>
        <time_frame>Day 22</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT population, day 22 with LOCF with Day 22 baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Albuterol</title>
            <description>Albuterol-HFA-MDI 180 mcg, four times a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-HFA-MDI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Baseline-adjusted area-under-the Effect Curve for Percent of Predicted FEV1 Over 6 Hours Post-dose on Day 22.</title>
            <units>Percent of predicted FEV1 * Hours</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="31.046" spread="3.531"/>
                  <measurement group_id="O2" value="21.338" spread="3.588"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0507</p_value>
            <method>ANCOVA</method>
            <method_desc>P-value from ANCOVA with terms for treatment, center, baseline as covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline-adjusted area-under-the Effect Curve for PEF Over 6 Hours Post-dose.</title>
        <time_frame>Day 22</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Albuterol</title>
            <description>Albuterol-HFA-MDI 180 mcg, four times a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-HFA-MDI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Baseline-adjusted area-under-the Effect Curve for PEF Over 6 Hours Post-dose.</title>
            <units>Liters/Minute*Hours</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <sub_title>Day 22 data analyzed using Day 1 Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="139.42" spread="25.782"/>
                  <measurement group_id="O2" value="96.842" spread="26.117"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 22 data analyzed using Day 22 Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="120.82" spread="17.486"/>
                  <measurement group_id="O2" value="90.693" spread="17.753"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.2375</p_value>
            <method>ANCOVA</method>
            <method_desc>Using Day 1 Baseline. P-value from ANCOVA with terms for treatment, center, baseline as covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.2186</p_value>
            <method>ANCOVA</method>
            <method_desc>Using Day 22 Baseline. P-value from ANCOVA with terms for treatment, center, baseline as covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Percent Change in Peak Expiratory Flow (PEF)</title>
        <description>The PEF test is conducted by having a person blow as hard as they can into a mouthpiece attached to a sensor that measures the amount of air blown over time. Maximum percent change in Peak Expiratory Flow (PEF) observed up to 2 hours following completion of dosing using Day 22 baseline.</description>
        <time_frame>Day 22</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT population, day 22 with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Albuterol</title>
            <description>Albuterol-HFA-MDI 180 mcg, four times a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-HFA-MDI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Maximum Percent Change in Peak Expiratory Flow (PEF)</title>
            <description>The PEF test is conducted by having a person blow as hard as they can into a mouthpiece attached to a sensor that measures the amount of air blown over time. Maximum percent change in Peak Expiratory Flow (PEF) observed up to 2 hours following completion of dosing using Day 22 baseline.</description>
            <units>Percentage of change</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17.558" spread="1.878"/>
                  <measurement group_id="O2" value="12.127" spread="1.907"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0403</p_value>
            <method>ANCOVA</method>
            <method_desc>P-value from ANCOVA with terms for treatment, center, baseline as covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Time (in Minutes) to Response Onset: the First Time That an Increase From Baseline in FEVl of at Least 15% is Noted in Participants Who Responded to the Medication.</title>
        <time_frame>Day 22</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT Participants who received albuterol.</population>
        <group_list>
          <group group_id="O1">
            <title>Albuterol</title>
            <description>Albuterol-HFA-MDI 180 mcg, four times a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-HFA-MDI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="51"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Time (in Minutes) to Response Onset: the First Time That an Increase From Baseline in FEVl of at Least 15% is Noted in Participants Who Responded to the Medication.</title>
            <units>Minutes</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Day 1 (N=9, placebo not analyzed)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17.73" spread="13.01"/>
                  <measurement group_id="O2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 22 (N=9, placebo not analyzed)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14.36" spread="8.13"/>
                  <measurement group_id="O2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 22 with LOCF (N=10, placebo not analyzed)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13.42" spread="8.22"/>
                  <measurement group_id="O2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Time (in Minutes) to Response Onset: the First Time That an Increase From Baseline in PEF of at Least 15% is Noted</title>
        <time_frame>Day 22</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants who received albuterol and who responded to treatment within the first 30 minutes. Only data from those participants who responded to the medication at each measurement were analyzed. There were different numbers of responders at each measurement. Data from participants in the Placebo arm were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Albuterol</title>
            <description>Albuterol-HFA-MDI 180 mcg, four times a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-HFA-MDI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Time (in Minutes) to Response Onset: the First Time That an Increase From Baseline in PEF of at Least 15% is Noted</title>
            <units>Minutes</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Day 1 (N=23, placebo not analyzed)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18.04" spread="11.04"/>
                  <measurement group_id="O2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 22 (N=21, placebo not analyzed)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17.29" spread="11.57"/>
                  <measurement group_id="O2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 22 with LOCF (N=22, placebo not analyzed)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16.91" spread="11.43"/>
                  <measurement group_id="O2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Time (in Minutes) to Response Onset: the First Time That an Increase From Baseline in FEVl of at Least 12% is Noted</title>
        <time_frame>Day 22</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants who received albuterol and who responded to treatment within the first 30 minutes. Only data from those participants who responded to the medication at each measurement were analyzed. There were different numbers of responders at each measurement. Data from participants in the Placebo arm were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Albuterol</title>
            <description>Albuterol-HFA-MDI 180 mcg, four times a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-HFA-MDI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Time (in Minutes) to Response Onset: the First Time That an Increase From Baseline in FEVl of at Least 12% is Noted</title>
            <units>Minutes</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Day 1 (N=17, placebo not analyzed)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14.48" spread="8.85"/>
                  <measurement group_id="O2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 22 (N=15, placebo not analyzed)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14.21" spread="11.21"/>
                  <measurement group_id="O2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 22 with LOCF (N=16, placebo not analyzed)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13.63" spread="11.07"/>
                  <measurement group_id="O2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Time (in Minutes) to Response Onset: the First Time That an Increase From Baseline in PEF of at Least 12% is Noted</title>
        <time_frame>Day 22</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants who received albuterol and who responded to treatment within the first 30 minutes. Only data from those participants who responded to the medication at each measurement were analyzed. There were different numbers of responders at each measurement. Data from participants in the Placebo arm were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Albuterol</title>
            <description>Albuterol-HFA-MDI 180 mcg, four times a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-HFA-MDI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Time (in Minutes) to Response Onset: the First Time That an Increase From Baseline in PEF of at Least 12% is Noted</title>
            <units>Minutes</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Day 1 (N=30, placebo not analyzed)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12.53" spread="8.83"/>
                  <measurement group_id="O2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 22 (N=29, placebo not analyzed)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16.72" spread="11.38"/>
                  <measurement group_id="O2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 22 with LOCF (N=30, placebo not analyzed)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16.47" spread="11.27"/>
                  <measurement group_id="O2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Time (in Minutes) to Maximum FEVl</title>
        <time_frame>Day 22</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants who received albuterol and who responded to treatment within the first 30 minutes. Only data from those participants who responded to the medication at each measurement were analyzed. There were different numbers of responders at each measurement. Data from participants in the Placebo arm were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Albuterol</title>
            <description>Albuterol-HFA-MDI 180 mcg, four times a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-HFA-MDI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Time (in Minutes) to Maximum FEVl</title>
            <units>Minutes</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Day 1 (N=51, N=51)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="43.95" lower_limit="32.03" upper_limit="51.73"/>
                  <measurement group_id="O2" value="45.25" lower_limit="30.32" upper_limit="62.82"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 22 with LOCF (N=52, N=51)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="41.54" lower_limit="29.55" upper_limit="45.67"/>
                  <measurement group_id="O2" value="61.05" lower_limit="46.53" upper_limit="120.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0647</p_value>
            <p_value_desc>For Day 1</p_value_desc>
            <method>Cox model separately for each day</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0005</p_value>
            <p_value_desc>For Day 22 with LOCF</p_value_desc>
            <method>Cox model separately for each study day</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Time (in Minutes) to Maximum PEF</title>
        <time_frame>Day 22</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Albuterol</title>
            <description>Albuterol-HFA-MDI 180 mcg, four times a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-HFA-MDI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Time (in Minutes) to Maximum PEF</title>
            <units>Minutes</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Day 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="41.50" lower_limit="34" upper_limit="64"/>
                  <measurement group_id="O2" value="35" lower_limit="33" upper_limit="65"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 22 with LOCF</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="34.5" lower_limit="22" upper_limit="50"/>
                  <measurement group_id="O2" value="63" lower_limit="35" upper_limit="115"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.5059</p_value>
            <p_value_desc>Day 1</p_value_desc>
            <method>Cox model separately for each study day</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0333</p_value>
            <p_value_desc>Day 22 with LOCF</p_value_desc>
            <method>Cox model separately for each study day</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Duration of Effect (in Hours) as Measured From the Time of Dosing to the Time at Which the FEVl First Decreases Below 15%</title>
        <time_frame>Day 22</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants who received albuterol and who responded to treatment within the first 30 minutes. Only data from those participants who responded to the medication at each measurement were analyzed. There were different numbers of responders at each measurement. Data from participants in the Placebo arm were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Albuterol</title>
            <description>Albuterol-HFA-MDI 180 mcg, four times a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-HFA-MDI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Duration of Effect (in Hours) as Measured From the Time of Dosing to the Time at Which the FEVl First Decreases Below 15%</title>
            <units>Hours</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Day 1 (N=9, placebo not analyzed)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.57" spread="2.23"/>
                  <measurement group_id="O2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 22 (N=9, placebo not analyzed)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.11" spread="2.56"/>
                  <measurement group_id="O2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 22 with LOCF (N=10, placebo not analyzed)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.83" spread="2.57"/>
                  <measurement group_id="O2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Duration of Effect (in Hours) as Measured From the Time of Dosing the Time at Which the FEVl First Decreases Below 12%</title>
        <time_frame>Day 22</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants who received albuterol and who responded to treatment within the first 30 minutes. Only data from those participants who responded to the medication at each measurement were analyzed. There were different numbers of responders at each measurement. Data from participants in the Placebo arm were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Albuterol</title>
            <description>Albuterol-HFA-MDI 180 mcg, four times a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-HFA-MDI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Duration of Effect (in Hours) as Measured From the Time of Dosing the Time at Which the FEVl First Decreases Below 12%</title>
            <units>Hours</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Day 1 (N=17, placebo not analyzed)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.62" spread="2.31"/>
                  <measurement group_id="O2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 22 (N=15, placebo not analyzed)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.25" spread="2.51"/>
                  <measurement group_id="O2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 22 with LOCF (N=16, placebo not analyzed)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.07" spread="2.54"/>
                  <measurement group_id="O2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Duration of Effect (in Hours) as Measured From the Time of Dosing the Time at Which the PEF First Decreases Below 15%</title>
        <time_frame>Day 22</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants who received albuterol and who responded to treatment within the first 30 minutes. Only data from those participants who responded to the medication at each measurement were analyzed. There were different numbers of responders at each measurement. Data from participants in the Placebo arm were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Albuterol</title>
            <description>Albuterol-HFA-MDI 180 mcg, four times a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-HFA-MDI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Duration of Effect (in Hours) as Measured From the Time of Dosing the Time at Which the PEF First Decreases Below 15%</title>
            <units>Hours</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Day 1 (N=23, placebo not analyzed)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.64" spread="2.43"/>
                  <measurement group_id="O2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 22 (N=21, placebo not analyzed)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.46" spread="2.39"/>
                  <measurement group_id="O2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 22 with LOCF (N=22, placebo not analyzed)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.41" spread="2.34"/>
                  <measurement group_id="O2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Duration of Effect (in Hours) as Measured From the Time of Dosing the Time at Which the PEF First Decreases Below 12%</title>
        <time_frame>Day 22</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants who received albuterol and who responded to treatment within the first 30 minutes. Only data from those participants who responded to the medication at each measurement were analyzed. There were different numbers of responders at each measurement. Data from participants in the Placebo arm were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Albuterol</title>
            <description>Albuterol-HFA-MDI 180 mcg, four times a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-HFA-MDI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Duration of Effect (in Hours) as Measured From the Time of Dosing the Time at Which the PEF First Decreases Below 12%</title>
            <units>Hours</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Day 1 (N=30)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.77" spread="2.54"/>
                  <measurement group_id="O2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 22 (N=29)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.38" spread="2.48"/>
                  <measurement group_id="O2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 22 with LOCF (N=30)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.34" spread="2.44"/>
                  <measurement group_id="O2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Highest Daily Asthma Symptom Scores by Study Week</title>
        <description>Highest daily asthma symptom scores by study week. For this assessment, patients self-evaluate and record on the diary card the following asthma symptoms experienced during the day (i.e. last 12-14 hours): wheeze, shortness of breath, cough, tightness of chest. The worst of these symptoms will be scored daily as 0 = No symptoms occurred, 1 = Symptom occurred but did not interfere with daily activity, 2 = Symptom occurred but was sometimes annoying or interfered with daily activity, 3 = Symptom present even at rest and was annoying or interfered with daily activity</description>
        <time_frame>Week 3</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT population. The differences in number of responses analyzed reflects missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Albuterol</title>
            <description>Albuterol-HFA-MDI 180 mcg, four times a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-HFA-MDI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Highest Daily Asthma Symptom Scores by Study Week</title>
            <description>Highest daily asthma symptom scores by study week. For this assessment, patients self-evaluate and record on the diary card the following asthma symptoms experienced during the day (i.e. last 12-14 hours): wheeze, shortness of breath, cough, tightness of chest. The worst of these symptoms will be scored daily as 0 = No symptoms occurred, 1 = Symptom occurred but did not interfere with daily activity, 2 = Symptom occurred but was sometimes annoying or interfered with daily activity, 3 = Symptom present even at rest and was annoying or interfered with daily activity</description>
            <units>Units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <sub_title>Week 1 (N=50, N=50)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.370" spread="0.070"/>
                  <measurement group_id="O2" value="0.442" spread="0.070"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 2 (N=50, N=49)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.376" spread="0.070"/>
                  <measurement group_id="O2" value="0.547" spread="0.071"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 3 (N=47, N=48)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.336" spread="0.072"/>
                  <measurement group_id="O2" value="0.474" spread="0.071"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.4674</p_value>
            <p_value_desc>Week 1</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>P-value from ANCOVA with terms for treatment, center, week, week x treatment, baseline as covariate, subject as random</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0840</p_value>
            <p_value_desc>Week 2</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>P-value from ANCOVA with terms for treatment, center, week, week x treatment, baseline as covariate, subject as random</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.1699</p_value>
            <p_value_desc>Week 3</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>P-value from ANCOVA with terms for treatment, center, week, week x treatment, baseline as covariate, subject as random</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Asthma-related Nocturnal Awakenings Per Week Requiring the Use of Rescue Medication</title>
        <time_frame>Week 3</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Albuterol</title>
            <description>Albuterol-HFA-MDI 180 mcg, four times a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-HFA-MDI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Number of Asthma-related Nocturnal Awakenings Per Week Requiring the Use of Rescue Medication</title>
            <units>Number of awakenings</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Run-In (N=52, N=51)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.15" spread="2.97"/>
                  <measurement group_id="O2" value="1.06" spread="2.44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 1 (N=51, N=50)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.14" spread="3.25"/>
                  <measurement group_id="O2" value="1.00" spread="2.84"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 2 (N=51, N=49)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.16" spread="3.82"/>
                  <measurement group_id="O2" value="0.73" spread="1.97"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 3 (N=49, N=48)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.65" spread="2.21"/>
                  <measurement group_id="O2" value="1.33" spread="3.13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Daily a.m. Pre-dose PEF</title>
        <time_frame>Week 3</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Albuterol</title>
            <description>Albuterol-HFA-MDI 180 mcg, four times a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-HFA-MDI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Daily a.m. Pre-dose PEF</title>
            <units>Liters/minute</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <sub_title>Week 1 (N=51, N=50)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="229.65" spread="4.800"/>
                  <measurement group_id="O2" value="219.72" spread="4.854"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 2 (N=51, N=49)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="229.90" spread="4.800"/>
                  <measurement group_id="O2" value="218.97" spread="4.870"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 3 (N=49, N=48)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="231.28" spread="4.820"/>
                  <measurement group_id="O2" value="221.73" spread="4.880"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.1391</p_value>
            <p_value_desc>Week 1</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>P-value from ANCOVA with terms for treatment, center, week, week x treatment, baseline as covariate, subject as random</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.1043</p_value>
            <p_value_desc>Week 2</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>P-value from ANCOVA with terms for treatment, center, week, week x treatment, baseline as covariate, subject as random</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.1570</p_value>
            <p_value_desc>Week 3</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>P-value from ANCOVA with terms for treatment, center, week, week x treatment, baseline as covariate, subject as random</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Average Number of Puffs of Rescue Medication Per 24 Hour Period</title>
        <time_frame>Week 3</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Albuterol</title>
            <description>Albuterol-HFA-MDI 180 mcg, four times a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo-HFA-MDI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Average Number of Puffs of Rescue Medication Per 24 Hour Period</title>
            <units>Number of puffs per day</units>
            <param>Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Week 1 (N=51, N=50)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.074" lower_limit="0.009" upper_limit="0.138"/>
                  <measurement group_id="O2" value="0.075" lower_limit="0.011" upper_limit="0.139"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 2 (N=51, N=49)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.084" lower_limit="0.011" upper_limit="0.158"/>
                  <measurement group_id="O2" value="0.088" lower_limit="0.013" upper_limit="0.163"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 3 (N=49, N=48)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.078" lower_limit="0.010" upper_limit="0.146"/>
                  <measurement group_id="O2" value="0.088" lower_limit="0.013" upper_limit="0.163"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.9846</p_value>
            <p_value_desc>Week 1</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>P-value from zero inflated mixed Poisson regression with terms for treatment, center, week, week x treatment, baseline as covariate, subject as random</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.9447</p_value>
            <p_value_desc>Week 2</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Pvalue from zero inflated mixed Poisson regression with terms for treatment, center, week, week x treatment, baseline as covariate, subject as random</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.8326</p_value>
            <p_value_desc>Week 3</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Pvalue from zero inflated mixed Poisson regression with terms for treatment, center, week, week x treatment, baseline as covariate, subject as random</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Albuterol</title>
          <description>Albuterol-HFA-MDI 180 mcg, four times a day</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo-HFA-MDI</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor has the right 60 days before submission for publication to review/provide comments. If review shows that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for up to 90 additional days to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure of multicenter data, but not longer than 12 months from study completion/termination at all participating sites.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Teva Study Physician</name_or_title>
      <organization>Teval Global Respiratory Research LLC</organization>
      <phone>215-293-6482</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
